Credo Life Sciences Private Limited

Credo Life Sciences Private Limited - pharma in Hyderabad, Telangana, India. FY 2026 financials & compliance.
CIN U24232TG2014PTC112849 Incorporated 03 July 2014 ROC Hyderabad HQ Hyderabad, Telangana, India
Active Private Limited Company pharma MSME · Medium
Revenue · FY 2024
₹100.47 Cr
▲ 22% YoY
Net profit · FY 2024
₹6.53 Cr
Net margin 6.5%
EBITDA · FY 2024
₹14.65 Cr
EBITDA margin 14.6%
Authorised capital
₹15.5 Cr
Registered with MCA
Paid-up capital
₹13.5 Cr
Issued & subscribed
Open charges
₹32.48 Cr
Secured borrowings
Company age
12 yrs
Est. 2014
Employees · EPFO
193
Provident fund records

About Credo Life Sciences Private Limited

Data last updated:

Credo Life Sciences Private Limited is a private limited company based in Hyderabad, Telangana, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 03 July 2014 and has been in existence for over 12 years.

The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U24232TG2014PTC112849. Its GSTIN is 36AAFCC7068Q1ZX (Telangana). The company holds 2 GST registrations, of which 1 is active.

The company has an authorised share capital of ₹15.5 Cr and a paid-up capital of ₹13.5 Cr. It is led by directors including Siva Rama Prasad Aluru (Managing Director) and Kandru Madhavarao.

Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at Hyderabad, Telangana.

As per the financials filed for FY 2024, the company reported a revenue of ₹100.47 Cr, a growth of 22% compared to the previous year. For the same year it recorded a net profit of ₹6.53 Cr (net margin 6.5%) and EBITDA of ₹14.65 Cr (EBITDA margin 14.6%). Revenue has grown at a compounded annual rate (CAGR) of 26% over three years and 31% over five years.

The company has about 193 employees on its provident fund (EPFO) records.

The company is associated with 1 brand: Credo Life. As per MCA filings, the company has open charges of ₹32.48 Cr on record. Court records list 1 case involving the company, including 1 filed against it. The company has 6 deals on record (3 funding rounds, 2 secondary share transfers, 1 rights issue), with disclosed funding of ₹11.39 Cr; the latest was in January 2023. Its 7 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 3 smaller; the largest is Nabros Pharma Private Limited with revenue of ₹101.03 Cr.

Credo Life Sciences Private Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-TS-02-0002373). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website credolife.in.

Company details

CIN U24232TG2014PTC112849
Registration Number 112849
Incorporation Date 03 July 2014
ROC Hyderabad
Listing Status Unlisted
Company Status Active
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-TS-02-0002373

CIN history

Credo Life Sciences has one previous CIN (Corporate Identification Number): U24232AP2014PTC094778. The current CIN is U24232TG2014PTC112849, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
U24232TG2014PTC112849Current
U24232AP2014PTC094778Previous

Recognitions & Rankings of Credo Life Sciences

MSME (Udyam registered) Ministry of MSME
Category
Medium (2022-23)
Udyam number
UDYAM-TS-02-0002373

Contact details

Credo Life Sciences Private Limited's registered office is in Hyderabad, Telangana. Its website is credolife.in. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Registered Address
    Flat No. 1101 Vasavi Sky City. 11th Floor Tower – 1, Telecom Nagar Gachibowli, Hyderabad, Telangana, India – 500081
  • Industry
    Pharma, Drug Formulation & Development

To see the full contact details of Credo Life Sciences Private Limited, buy the company report.

Comprehensive company report
Credo Life Sciences Private Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Credo Life Sciences operates one associated brand: Credo Life. Each brand links to its own profile.

BrandDescriptionWebsite
Supplies specialized pellets and taste-masking granules for global markets.credolife.in

Business activity

The main business activity of Credo Life Sciences is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Credo Life Sciences Private Limited, buy the company report.

Financials of Credo Life Sciences Private Limited

FY 2024 filings available

Credo Life Sciences Private Limited reported revenue of ₹100.47 Cr (up 22% YoY) for FY 2024.

Revenue · FY 2024
₹100.47 Cr ▲ 22%
Net profit · FY 2024
₹6.53 Cr margin 6.5%
EBITDA · FY 2024
₹14.65 Cr margin 14.6%

Compounded Annual Growth Rate (CAGR)

Revenue CAGR growth
1 year
▲ 22%
3 years · compounded
▲ 26%
5 years · compounded
▲ 31%
EBITDA CAGR growth
1 year
▲ 68%
3 years · compounded
▲ 29%
5 years · compounded
▲ 95%

Revenue has grown at a compounded annual rate (CAGR) of 31% over five years, including 22% growth in the latest year. EBITDA rose 68% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.

Financial Statement Summary

MetricsFY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Profit and Loss Statement
Revenue from Operations
Other Income
Total Revenue₹100.47 Cr
Cost of Materials Consumed
Employee Benefit Expense
Finance Costs
Depreciation and Amortisation
Other Expenses
Total Expenses
EBITDA₹14.65 Cr
Profit Before Tax
Tax Expense
Net Profit (PAT)₹6.53 Cr
Balance Sheet
Share Capital
Reserves and Surplus
Net Worth (Total Equity)
Long-term Borrowings
Short-term Borrowings
Trade Payables
Total Liabilities
Fixed Assets
Investments
Inventories
Trade Receivables
Cash and Bank Balance
Total Assets

Financial Ratios

MetricsFY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Profitability
EBITDA Margin14.6%
Net Profit Margin6.5%
Return on Equity (ROE)
Return on Capital Employed (ROCE)
Return on Assets (ROA)
Liquidity and Debt
Current Ratio
Quick Ratio
Debt-to-Equity Ratio
Interest Coverage Ratio
Efficiency and Growth
Asset Turnover
Receivable Days
Payable Days
Inventory Days
Revenue Growth
Net Profit Growth

To see the full financial statements and ratios of Credo Life Sciences Private Limited, buy the company report.

Board of directors of Credo Life Sciences Private Limited

Credo Life Sciences has 3 current directors and 3 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Kandru MadhavaraoDirector01 Apr 201511 Years 7 MonthsCurrent
Siva Rama Prasad AluruManaging Director03 Jul 201412 Years 4 MonthsCurrent
Aluru Vamsi KrishnaDirector03 Jul 201412 Years 4 MonthsCurrent

Peer comparison

Credo Life Sciences Private Limited is compared with the 7 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Nabros Pharma Private Limited₹101.03 Cr (FY 2025)6.0%Ahmedabad, Gujarat, India
Instapill Private Limited₹100.92 Cr (FY 2025)11.0%Bangalore, Karnataka, India
Sotac Pharmaceuticals Limited₹100.88 Cr (FY 2025)-3.0%Sanand, Gujarat, India
Lake Chemicals Private Limited₹100.59 Cr (FY 2025)-5.0%Bangalore, Karnataka, India
Credo Life Sciences Private Limitedthis company₹100.47 Cr (FY 2024)₹6.53 Cr6.5%22.0%193Hyderabad, Telangana, India
Consern Pharma Limited₹100.37 Cr (FY 2025)-2.0%Ludhiana, Punjab, India
Medibios Laboratories Limited₹100.12 Cr (FY 2023)-2.0%
Synokem Lifesciences Private Limited₹99.46 Cr (FY 2025)108.0%New Delhi, Delhi, India

To see the full peer comparison of Credo Life Sciences Private Limited, buy the company report.

Auditor

Credo Life Sciences Private Limited is audited by K. Nagaraju & Associates for the financial year 2024.

Auditor firmFinancial yearFirm registration number
K. Nagaraju & AssociatesFY 2024002270S

Shareholding

The shareholding of Credo Life Sciences Private Limited is on record for 5 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.

Shareholder categoryFY 2024FY 2023FY 2022FY 2021FY 2020
Promoters
Domestic institutional investors (DII)
Foreign institutional investors (FII)
Public
Others

To see the full shareholding pattern of Credo Life Sciences Private Limited, buy the company report.

Charges & borrowings

Open charges
₹32.48 Cr
Satisfied charges
None
Breakdown by lending institutions
Indian Bank₹32.13 Cr
Hdfc Bank Limited₹0.35 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
19 Feb 2025101061800Indian Bank₹1.98 CrOpen
18 Nov 2024101010188Indian Bank₹2.15 CrOpen
03 Jan 2023100696697Hdfc Bank Limited₹35 LakhOpen
31 Oct 2016100068549Indian Bank₹28 CrOpen

To see the full charge records of Credo Life Sciences Private Limited, buy the company report.

Total charge records: 4 View all charges

Deals & funding

Credo Life Sciences Private Limited has 6 deals on record (3 funding rounds, 2 secondary share transfers, 1 rights issue), with disclosed funding of ₹11.39 Cr; the latest was in January 2023.

Total deals
6
Funding rounds
3
Secondary share transfers
2
Rights issue
1
Disclosed funding
₹11.39 Cr

Deals on record (5 of 6)

WhenDealAmountParties
Jan 2023Secondary share transferUndisclosedBuyer: 3 individuals
Seller: 3 individuals
Oct 2021Secondary share transferUndisclosedBuyer: 2 individuals
Seller: 3 individuals
Jun 2021Rights issue₹2 CrInvestors: 2 individuals
Jun 2017Funding round₹2.5 CrInvestors: 4 individuals
Jul 2016Funding round₹2.28 CrInvestors: 4 individuals

To see the full deal history of Credo Life Sciences Private Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Credo Life Sciences Private Limited was last rated by Icra on 17 Feb 2022.

Rating agencyRated onRating
Icra17 Feb 2022

To see the full credit ratings and regulatory alerts of Credo Life Sciences Private Limited, buy the company report.

MSME payment delays

No delayed payments to MSME suppliers are on our record for Credo Life Sciences Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.

Employees & EPFO

Credo Life Sciences Private Limited has a workforce of 193 employees on its EPFO records as of May 2026, across 1 active EPFO establishment.

Employee count
193
Active EPFO establishments
1
Employee growth
4.9%

Headcount by financial year

Financial yearEmployees (EPFO)
FY 2026-27193
FY 2025-26
FY 2024-25
FY 2023-24
FY 2022-23
FY 2021-22
FY 2020-21
FY 2019-20
FY 2018-19
FY 2017-18
FY 2016-17

To see the full employee and EPFO history of Credo Life Sciences Private Limited, buy the company report.

GST

Credo Life Sciences has 2 GST registrations: 1 active and 1 cancelled or inactive.

Total GSTINs
2
Active
1
Cancelled / inactive
1
GSTINStateStatusRegistered on
36AAFCC7068Q1ZXTelanganaActive01 Jul 2017

To see the full GST registrations and return filing status of Credo Life Sciences Private Limited, buy the company report.

Recent activity

Credo Life Sciences Private Limited has 6 board changes on record since 2014: 3 appointments and 3 cessations. The latest: Venkata Narayana Reddy Konda ceased to be Company Secretary on 06 Jul 2021.

Charges
A charge with Indian Bank of Rs. 28.00 Cr registered on 31 Oct 2016 with Charge ID 100068549 was modified on 27 Aug 2025.
Charges
A charge with Indian Bank amounted to Rs. 1.98 Cr with Charge ID 101061800 was registered on 19 Feb 2025.
Charges
A charge with Indian Bank amounted to Rs. 2.15 Cr with Charge ID 101010188 was registered on 18 Nov 2024.
AGM
Credo Life Sciences Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records.
Filing
Credo Life Sciences Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Hyderabad.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.35 Cr with Charge ID 100696697 was registered on 03 Jan 2023.
Ceased
Venkata Narayana Reddy Konda ceased to be Company Secretary.
Charges
A charge with Indian Bank amounted to Rs. 28.00 Cr with Charge ID 100068549 was registered on 31 Oct 2016.
Ceased
Kandru Madhavarao ceased to be Additional Director.
Appointed
Kandru Madhavarao was appointed as Director.
Ceased
Siva Rama Prasad Aluru ceased to be Director.
Appointed
Aluru Vamsi Krishna was appointed as Director.

2 earlier events are in the company report.

Frequently asked questions

Credo Life Sciences is an active private limited company based in Hyderabad, Telangana, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 03 July 2014 (12+ years old) and is registered under CIN U24232TG2014PTC112849.

Credo Life Sciences has 3 current directors:

The latest financial statements of Credo Life Sciences on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 September 2024. Year-wise statements from 2015 are in the company report.

The GSTIN of Credo Life Sciences is 36AAFCC7068Q1ZX, registered in Telangana. The company has 2 GST registrations in all, of which 1 is active and 1 is cancelled or inactive.

The CIN (Corporate Identification Number) of Credo Life Sciences is U24232TG2014PTC112849. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Credo Life Sciences has 1 court case on record: 1 filed against it.

Credo Life Sciences was incorporated on 03 July 2014, making it 12+ years old. It is registered with the Registrar of Companies, Hyderabad.

Credo Life Sciences has 6 deals on record (3 funding rounds, 2 secondary share transfers, 1 rights issue), with disclosed funding of ₹11.39 Cr; the latest was in January 2023.

The peers of Credo Life Sciences by revenue are Nabros Pharma Private Limited, Instapill Private Limited, Sotac Pharmaceuticals Limited, Lake Chemicals Private Limited, Consern Pharma Limited and 2 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).

Venkata Narayana Reddy Konda ceased to be Company Secretary on 06 Jul 2021. Kandru Madhavarao ceased to be Additional Director on 18 Sep 2015. Kandru Madhavarao was appointed as Director on 01 Apr 2015. Credo Life Sciences has 6 board changes on record in total.

Yes, Credo Life Sciences is registered as a medium enterprise under Udyam registration (number: UDYAM-TS-02-0002373).